Related Experiment Video
Updated: Feb 21, 2026
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.8K
PRAS40 signaling in tumor.
Dan Lv1, Lianying Guo1, Ting Zhang1
1Department of Pathophysiology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Oncotarget
|October 6, 2017
Summary
Proline-rich Akt substrate of 40 kDa (PRAS40) is crucial in cancer and metabolic disorders. Phosphorylated PRAS40 drives tumor progression, highlighting its potential as a novel therapeutic target.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- PRAS40 (proline-rich Akt substrate of 40 kDa) is a key regulator at the intersection of PI3K/Akt and mTOR signaling pathways.
- PRAS40 phosphorylation, influenced by growth factors, modulates these critical cellular pathways.
- Dysregulation of PRAS40 signaling is implicated in metabolic disorders and various cancers.
Purpose of the Study:
- To provide a comprehensive overview of PRAS40 signaling in tumor formation and progression.
- To explore the role of PRAS40 and its phosphorylation in oncogenesis.
- To identify PRAS40 as a potential biomarker and therapeutic target in oncology.
Main Methods:
- Literature review and synthesis of current research on PRAS40 signaling pathways.
- Analysis of PRAS40's role in cellular processes like proliferation, apoptosis, and metastasis.
- Examination of PRAS40 phosphorylation patterns in relation to tumor progression.
Main Results:
- PRAS40 phosphorylation is frequently associated with tumor progression in cancers such as melanoma and prostate cancer.
- PRAS40 deregulation contributes to tumorigenesis by altering cellular proliferation, apoptosis, senescence, and metastasis.
- PRAS40 acts as a critical signaling node influencing multiple cancer-related pathways.
Conclusions:
- PRAS40 plays a significant role in the initiation and advancement of various tumors.
- Phospho-PRAS40 serves as a potential predictive biomarker for tumor progression.
- Targeting PRAS40 or its phosphorylated form presents a promising therapeutic strategy for cancer treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
01:19Interactions Between Signaling Pathways
7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
02:07Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
01:22PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
02:17The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
01:24Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K